<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935480</url>
  </required_header>
  <id_info>
    <org_study_id>CH-2009.01</org_study_id>
    <nct_id>NCT00935480</nct_id>
  </id_info>
  <brief_title>IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients</brief_title>
  <acronym>IntensVIH</acronym>
  <official_title>IMPACT OF THERAPY INTENSIFICATION BY AN INTEGRASE INHIBITOR +/- CCR5 INHIBITOR ON THE LYMPHOID RESERVOIR FOR HIV-1 IN CHRONICALLY INFECTED PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of adding Isentress®, with or without Celsentri®, to effective
      conventional antiretroviral therapy (comprising at least 2 reverse transcriptase inhibitors
      and one boosted protease inhibitor), on residual HIV replication and blood cell and
      gut-associated lymphoid tissue reservoirs (reverse transcriptase inhibitors: RTIs, boosted
      protease inhibitors: PI/r).

      To evaluate the effect of therapy intensification by means of an integrase inhibitor with or
      without CCR5 inhibitor treatment on the lymphoid reservoir in patients chronically infected
      with HIV-1, successfully treated with &quot;conventional triple therapy&quot;, measured by:

        -  residual plasma replication between 0 and 50 copies/ml

        -  intracellular HIV RNA levels in circulating lymphocytes (PBMC) and lymphocytes in
           gut-associated rectal lymphoid tissue (RL).

        -  proviral HIV DNA levels in PBMC and RL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">August 8, 2014</completion_date>
  <primary_completion_date type="Actual">November 12, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>residual plasma replication between 0 and 50 copies/ml</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>intracellular HIV RNA levels in circulating lymphocytes (PBMC) and lymphocytes in gut-associated rectal lymphoid tissue (RL</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>proviral HIV DNA levels in PBMC and RL</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 counts</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 activation levels</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HAART+Raltegravir 12 months (+/-) Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HAART</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isentress®</intervention_name>
    <description>P.O, 1 tablet containing 400 mg every 12 hours</description>
    <arm_group_label>HAART+Raltegravir 12 months (+/-) Maraviroc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celsentri®</intervention_name>
    <description>p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)</description>
    <arm_group_label>HAART+Raltegravir 12 months (+/-) Maraviroc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, aged over 18 years

          -  HIV infection confirmed by Western Blot

          -  Karnofsky score &gt; 80%

          -  Treatment-experienced patients having received combined antiretroviral therapy
             including at least 2 RTI and 1 PI/r for at least 12 months with plasma viral load &lt;50
             copies/ml for at least 6 months

          -  Stable first-line treatment (or other, if changes were not made for reasons relating
             to viral resistance) with 2 RTIs and 1 PI/r

          -  Proper safety and compliance for the ongoing combination;

          -  Patient agreeing to undergo 3 proctosigmoidoscopy examinations over a 12-month period;

          -  Plasma HIV-1 RNA &lt;50 copies/ml at inclusion;

          -  Circulating CD4 &gt;200/mm3 at inclusion;

          -  Isentress® and Celsentri®-naïve patients

          -  No contraindications to the use of the investigational products

          -  Written, informed consent, obtained from the patient or his/her legal representative.

        Exclusion Criteria:

          1. Opportunistic infection or active tumor disease

          2. Chronic diarrhea, malabsorption, progressive enteric infection

          3. Aged under 18 years

          4. Pregnancy - breast-feeding ( a pregnancy test will be done at the inclusion visit)

          5. Co-infection with HIV-2

          6. History of immunomodulator treatment (interleukin-2, alpha-interferon)

          7. Ongoing treatment of HBV or HCV co-infection

          8. Blood constitution disorders

          9. Contraindications to the administration of raltegravir or maraviroc

         10. Circulating CD4 nadir &lt;100/mm3 in the natural history of HIV-1 infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Service d'infectiologie</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Toulon La Seyne sur mer</name>
      <address>
        <city>Toulon</city>
        <zip>83500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>INTEGRASE INHIBITOR</keyword>
  <keyword>Inhibitor on the lymphoid reservoir</keyword>
  <keyword>Residual HIV replication</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Integrase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

